Draft Guidance Doc From FDA Details Lab Accreditation Pilot
Executive Summary
The US FDA detailed its proposed approach to the Accreditation Scheme for Conformity Assessment in a new draft guidance document. The ASCA will allow accredited labs to certify that manufacturers meet international conformance standards, which the agency hopes will help streamline the device approval process.
You may also be interested in...
Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Conformity And Confidence: US FDA Seeks To Build Trust In Pre-Market Standards Declarations With ASCA Pilot
FDA hopes the Accreditation Scheme for Conformity Assessment pilot will make it easier to trust the declarations of conformity to standards that are made by device-makers in pre-market submissions, rather than having to ask a lot of time-consuming questions. ASCA, included in the latest FDA user-fee agreement, also has important implications for the agency's global harmonization efforts. But many questions remain about its value and viability; they were on display at a recent two-day workshop at the agency's headquarters.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.